No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients
No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients
复制标题
DOI：
10.1196/annals.1299.137
复制
发表时间：
2003-01-01
期刊：
影响因子：
--
通讯作者：
Gargouri, A
中科院分区：
文献类型：
--
作者：
Mabrouk, I;Baccouche, S;Gargouri, A
TP53基因在人类癌症中经常发生突变，携带几种多态性。信息量最大、研究最多的是密码子72；一个碱基将精氨酸（CGC）变成脯氨酸（CCC）。精氨酸形式被认为是癌症发展的重要风险因素。然而，关于这种多态性的各种报告是有争议的。我们采用改进的PCR-RFLP方法，对我国两个地区的膀胱癌和乳腺癌两组患者以及健康对照进行了相同的调查。Arg/Arg、Arg/Pro和Pro/Pro基因型数量分别为：第一组患者（47例）和对照组（34例）分别为21、23、3和13、19、2个基因型；第二组患者（30人）和对照组（49人）分别为18,9,3和19,26,4。基因型和等位基因频率的统计分析显示，两组患者与对照组之间没有差异，但第二组纯合子与杂合子之间存在微弱差异，卡方为4.1 (P = 0.045)；乳腺癌患者的数量实际上很低（30人），为了评估这样的结论，应该增加乳腺癌患者的数量。因此，我们的总体结果与乳腺癌和膀胱癌中TP53密码子72多态性相关的高风险不一致。
The TP53 gene, frequently mutated in human cancers, carries several polymorphisms. The one most informative and studied concerns codon 72; a single base changes the CGC (arginine) to CCC (proline). The arginine form was considered to be a significant risk factor in the development of cancer. However, various reports on this polymorphism are controversial. We carried out the Same investigation in two groups of patients, a group with bladder cancer and another with breast cancer, and in healthy controls in two regions of our country, using an improved PCR-RFLP method. The number of Arg/Arg, Arg/Pro, and Pro/Pro genotypes was as follows: 21, 23, 3 and 13, 19, 2 for patients (total 47) and controls (34), respectively, in the first group; 18, 9, 3 and 19, 26, 4 for patients (30) and controls (49), respectively, in the second group. Statistical analysis of the genotype and allele frequencies did not reveal any difference between patients and controls in both groups except for a weak difference-between the homozygotes to heterozygotes in the second group with a chi square of 4.1 (P = 0.045); the number of breast cancer patients is actually low (30) and should be increased in order to assess such a conclusion. Our overall results are therefore not consistent with a high risk associated with TP53 codon 72,polymorphism in breast and in bladder cancers.